亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

医学 结直肠癌 内科学 循环肿瘤DNA 佐剂 肿瘤科 化疗 阶段(地层学) 辅助化疗 辅助治疗 癌症 生物 古生物学 乳腺癌
作者
Jeanne Tie,Joshua D. Cohen,Kamel Lahouel,Serigne Lo,Yuxuan Wang,Suzanne Kosmider,Rachel Wong,Jeremy Shapiro,Margaret Lee,Sam Harris,Adnan Khattak,Matthew Burge,Marion Harris,James Lynam,Louise Nott,Fiona Day,Theresa Hayes,Sue‐Anne McLachlan,Belinda Lee,Janine Ptak
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:386 (24): 2261-2272 被引量:1022
标识
DOI:10.1056/nejmoa2200075
摘要

BACKGROUND: The role of adjuvant chemotherapy in stage II colon cancer continues to be debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence. The benefit of adjuvant chemotherapy for ctDNA-positive patients is not well understood. METHODS: We conducted a trial to assess whether a ctDNA-guided approach could reduce the use of adjuvant chemotherapy without compromising recurrence risk. Patients with stage II colon cancer were randomly assigned in a 2:1 ratio to have treatment decisions guided by either ctDNA results or standard clinicopathological features. For ctDNA-guided management, a ctDNA-positive result at 4 or 7 weeks after surgery prompted oxaliplatin-based or fluoropyrimidine chemotherapy. Patients who were ctDNA-negative were not treated. The primary efficacy end point was recurrence-free survival at 2 years. A key secondary end point was adjuvant chemotherapy use. RESULTS: Of the 455 patients who underwent randomization, 302 were assigned to ctDNA-guided management and 153 to standard management. The median follow-up was 37 months. A lower percentage of patients in the ctDNA-guided group than in the standard-management group received adjuvant chemotherapy (15% vs. 28%; relative risk, 1.82; 95% confidence interval [CI], 1.25 to 2.65). In the evaluation of 2-year recurrence-free survival, ctDNA-guided management was noninferior to standard management (93.5% and 92.4%, respectively; absolute difference, 1.1 percentage points; 95% CI, -4.1 to 6.2 [noninferiority margin, -8.5 percentage points]). Three-year recurrence-free survival was 86.4% among ctDNA-positive patients who received adjuvant chemotherapy and 92.5% among ctDNA-negative patients who did not. CONCLUSIONS: A ctDNA-guided approach to the treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival. (Supported by the Australian National Health and Medical Research Council and others; DYNAMIC Australian New Zealand Clinical Trials Registry number, ACTRN12615000381583.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
呆萌的鞯完成签到,获得积分10
6秒前
科目三的应助被笑点低听枫采纳,获得30
13秒前
酷酷海豚完成签到,获得积分10
23秒前
soleil发布了新的文献求助10
24秒前
30秒前
kbcbwb2002完成签到,获得积分0
30秒前
传统的艳完成签到,获得积分10
39秒前
着急的如波完成签到,获得积分10
40秒前
obedVL完成签到,获得积分10
43秒前
45秒前
46秒前
zhengjia发布了新的文献求助10
49秒前
张阳发布了新的文献求助10
49秒前
55秒前
1分钟前
1分钟前
suge完成签到,获得积分10
1分钟前
乐乐的应助被爱学习的doge采纳,获得10
1分钟前
赘婿的应助被爱学习的doge采纳,获得10
1分钟前
ding的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
wanci的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
1分钟前
今后的应助被爱学习的doge采纳,获得10
1分钟前
orixero的应助被爱学习的doge采纳,获得30
1分钟前
1分钟前
1分钟前
1分钟前
舒心鞋垫完成签到,获得积分10
1分钟前
华仔的应助被爱学习的doge采纳,获得10
1分钟前
李爱国的应助被爱学习的doge采纳,获得50
1分钟前
1分钟前
赘婿的应助被爱学习的doge采纳,获得10
1分钟前
小马甲的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
1分钟前
Owen的应助被爱学习的doge采纳,获得10
1分钟前
斯文败类的应助被爱学习的doge采纳,获得30
1分钟前
华仔的应助被爱学习的doge采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179924
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808379
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918